Stockscreener 앱 받기
2.34
4.00%
0.09
시간 외 거래:
2.38
0.04
+1.71%
전일 마감가:
$2.25
열려 있는:
$2.24
하루 거래량:
302.26K
Relative Volume:
2.15
시가총액:
$65.24M
수익:
-
순이익/손실:
$-14.14M
주가수익비율:
-2.5435
EPS:
-0.92
순현금흐름:
$-12.64M
1주 성능:
+17.59%
1개월 성능:
+15.84%
6개월 성능:
+10.90%
1년 성능:
+11.96%
1일 변동 폭
$2.24
$2.47
1주일 범위
$1.89
$2.47
52주 변동 폭
$1.26
$2.71
Immix Biopharma Inc Stock (IMMX) Company Profile
명칭
Immix Biopharma Inc
전화
(888) 958-1084
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
IMMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
2.34 | 55.48M | 0 | -14.14M | -12.64M | -0.92 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Immix Biopharma — Positive newsflow continues for NEXICART-2 - Smartkarma
Immix Biopharma accelerates NEXICART-2 trial enrollment By Investing.com - Investing.com South Africa
Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory AL Amyloidosis Trial Nexicart-2 - marketscreener.com
Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Sto - GuruFocus
Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Stock News - GuruFocus
Immix Biopharma accelerates NEXICART-2 trial enrollment - Investing.com
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - marketscreener.com
Immix Amyloidosis Trial Surges: 10 New Sites Added, ASCO Data Presentation Coming - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Trading Up 15.3% – Should You Buy? - Defense World
Immix Biopharma reports promising trial results for NXC-201 - Investing.com Australia
Immix Biopharma reports promising trial results for NXC-201 By Investing.com - Investing.com India
Immix Biopharma Reports Positive ASCO Abstract Results for NXC-201 from NEXICART-2 Trial in Relapsed/Refractory AL Amyloidosis - Nasdaq
Immix Biopharma Announces Positive Results for NXC-201 at - GlobeNewswire
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Yahoo Finance
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling ... - Eagle-Tribune
Immix Biopharma to Host KOL Event to Discuss NXC-201 - GlobeNewswire
We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate - Yahoo Finance
Immix Biopharma — Steady progress in Q125 - Smartkarma
Immix Biopharma Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Immix Biopharma (IMMX) to Release Earnings on Thursday - Defense World
Favourable Signals For Immix Biopharma: Numerous Insiders Acquired Stock - simplywall.st
Immix Biopharma Announces Oral Presentation of NXC-201 Phase 1/2 Trial Data at ASCO 2025 - Nasdaq
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025 - GlobeNewswire
Groundbreaking CAR-T Therapy for AL Amyloidosis: First US Trial Data Earns Prestigious ASCO Spotlight - Stock Titan
Immix Biopharma — All eyes on NEXICART-2 - Smartkarma
Immix Biopharma (IMMX) Expected to Announce Earnings on Friday - Defense World
Immix Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Immix Biopharma Inc. (IMMX) reports earnings - Quartz
Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Thursday - Defense World
Immix Biopharma — NXC-201 receives FDA RMAT designation - Smartkarma
SBI Securities Co. Ltd. Purchases New Stake in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix Biopharma (NASDAQ:IMMX) Trading Down 9% – Here’s Why - Defense World
HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat
FDA Awards RMAT Designation to NXC-201 for Relapsed/Refractory AL Amyloidosis - OncLive
Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright - MSN
Immix Biopharma stock holds $7 target, Buy rating at H.C. Wainwright By Investing.com - Investing.com South Africa
Immix Biopharma’s (IMMX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Immix Biopharma’s CAR-T NXC-201 Snags FDA RMAT Designation for Light Chain Amyloidosis - CGTLive™
Buy Rating for Immix Biopharma: Promising Clinical Advancements and Market Potential of NXC-201 - TipRanks
Immix Biopharma Says FDA Grants Regenerative Medicine Advanced Therapy Designation to NXC-201 Cell Therapy - Marketscreener.com
Immix Biopharma Receives FDA RMAT Designation For NXC-201 -February 10, 2025 at 10:15 am EST - Marketscreener.com
Think Lucid Group is Expensive? This Chart Might Change Your Mind. - The Globe and Mail
Immix Biopharma Receives FDA Regenerative Medicine Advanced - GlobeNewswire
Breakthrough: IMMX Secures Elite FDA Status for First-Ever AL Amyloidosis CAR-T Treatment - StockTitan
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024 - The Globe and Mail
Immix Biopharma : Presentation (IMMX Corporate presentation February 2025) - Marketscreener.com
Is Qualcomm Stock a Buy Even Without Huawei Deal? - The Globe and Mail
Several Insiders Invested In Immix Biopharma Flagging Positive News - Yahoo Finance
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 11.0% in December - MarketBeat
Geode Capital Management LLC Has $224,000 Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
FY2024 EPS Estimate for Immix Biopharma Lowered by Analyst - Defense World
Immix Biopharma Inc (IMMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):